enGene Therapeutics Inc. (ENGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $161.51M
Last updated: Nov 17, 2026 at 11:05 AM ET
enGene Therapeutics Inc. (ENGN) Stock Forecast
Analysts expect enGene Therapeutics (ENGN) to earn -$1.59 per share in the fiscal year ending Oct 31, 2027, on revenue of $5.41M. Of 9 analysts, 3 rate the stock Buy or Strong Buy, 6 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Oct 31, 2027 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.56, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 33% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 11.1% |
| Buy | 2 | 22.2% |
| Hold | 6 | 66.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
- Fiscal year ending Oct 31, 2027
- -$1.59
- EPS consensus, revenue $5.41M
- Next report
- Dec 22, 2026
- Estimated
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Oct 31, 2027 | -$1.59 | -$1.98 to -$1.03 | 7 | $5.41M | N/A | 7 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Jan 31, 2027 | -$0.38 | -$0.44 to -$0.30 | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 7 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Oct 31, 2027 | 3 | 4 |
| Quarter ending Jan 31, 2027 | 0 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Oct 31, 2027 has worsened from -$1.40.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Oct 31, 2027 | -$1.59 | -$1.51 | -$1.45 | -$1.44 | -$1.40 | N/A |
| Quarter ending Jan 31, 2027 | -$0.38 | -$0.34 | -$0.34 | -$0.34 | -$0.31 | N/A |
Frequently Asked Questions About ENGN
What is the ENGN stock forecast?
Consensus analyst estimates put enGene Therapeutics's EPS at -$1.59 for the fiscal year ending Oct 31, 2027, on revenue of $5.41M. The consensus rating from 9 analysts is Hold.
How do analysts rate ENGN stock?
Of 9 analysts covering enGene Therapeutics, 1 rates it Strong Buy, 2 Buy, 6 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from ENGN next year?
For the fiscal year ending Oct 31, 2027, the consensus EPS estimate is -$1.59, with estimates from -$1.98 to -$1.03 from 7 analysts.
What revenue do analysts expect from enGene Therapeutics next year?
For the fiscal year ending Oct 31, 2027, the consensus revenue estimate is $5.41M.
How many analysts cover ENGN?
9 analysts rate enGene Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Oct 31, 2027.
ENGN pages: Overview, Earnings, Forecast, Financials, Competitors